Showing 4351-4360 of 6036 results for "".
- Iveric Bio Receives FDA Approval for Izervay for Geographic Atrophyhttps://modernod.com/news/iveric-bio-receives-fda-approval-for-izervay-for-geographic-atrophy/2481764/Iveric Bio has received FDA approval for Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), parent company Astellas Pharma announced Friday night. Izervay, a new complem
- Glaucoma Treatment Research at Missouri S&T Receives NIH Fundinghttps://modernod.com/news/glaucoma-treatment-research-at-missouri-st-receives-nih-funding/2481759/The Missouri University of Science and Technology (S&T) announced that the National Institutes for Health (NIH) has awarded an R01 grant to Professor Hu Yang, PhD, who is S&T’s Doshi Endowed Department Chair of Chemical and Biochemical Engineering. The grant will prov
- Skyline Therapeutics’ Gene Therapy Candidate for Wet AMD Receives IND Clearancehttps://modernod.com/news/skyline-therapeutics-gene-therapy-candidate-for-namd-receives-ind-clearance/2481758/Skyline Therapeutics announced that the FDA has cleared the company’s investigational new drug (IND) application for a phase 1/2a clinical trial of SKG0106, a one-time intravitreally delivered adeno-associated virus (AAV) gene therapy for the treatment of wet age-related macular degene
- Apellis Provides Update on Review of Safety Events with Syfovre for Geographic Atrophyhttps://modernod.com/news/apellis-provides-update-on-review-of-safety-events-with-syfovre-for-geographic-atrophy/2481755/Apellis Pharmaceuticals provided an update on its review of rare events of retinal vasculitis reported in real-world treatment with Syfovre (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). “The safety of patients has always
- Okyo Pharma’s OK-101 Will Be Evaluated to Treat Neuropathic Corneal Pain in Study at Tuftshttps://modernod.com/news/okyo-pharmas-ok-101-will-be-evaluated-to-treat-neuropathic-corneal-pain-in-study-at-tufts/2481753/Okyo Pharma, which is developing OK-101 to treat the symptoms of dry-eye disease (DED), announced an agreement with Tufts Medical Center in Boston to conduct a 40-patient, open-label, clinical trial evaluating the efficacy and safety of OK-101 in patients with neuropathic corneal pain (NCP)
- HelpMeSee and USAID Partner to Train New Cataract Specialists to Provide Surgical Care for India's Cataract Blindhttps://modernod.com/news/helpmesee-and-usaid-partner-to-train-new-cataract-specialists-to-provide-surgical-care-for-indias-cataract-blind/2481752/HelpMeSee announced a new partnership with the United States Agency for International Development (USAID) American Schools and Hospitals Abroad (ASHA) initiative to train 100 new cataract specialists to help restore sight to India's cataract blind. Through this agreement, ASHA has p
- Glauconix Changes Name to Humonixhttps://modernod.com/news/glauconix-changes-name-to-humonix/2481751/Glauconix Biosciences has changed its name to Humonix Biosciences as the company has expanded beyond glaucoma to technology can support various cell types. "What began as a specialization in glaucoma therapeutics has become a launchpad for developing new fibrotic and vascular
- Verséa Ophthalmics Will Distribute Celularity’s Biovance and Biovance 3L Ocular Products in the United Stateshttps://modernod.com/news/versea-ophthalmics-will-distribute-celularitys-biovance-and-biovance-3l-ocular-products-in-the-united-states/2481750/Celularity and Verséa Ophthalmics announced that the companies have entered into an exclusive United States commercialization agreement under which Verséa will distribute Celularity’s Biovance and Biovance 3L ocular products. The products are designed to support the
- Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302https://modernod.com/news/opthea-announces-sozinibercept-as-the-nonproprietary-drug-name-for-opt-302/2481747/Opthea announced that the American Medical Association’s United States Adopted Names (USAN) Council has approved the nonproprietary drug name “sozinibercept” for the company’s lead biologic drug candidate, OPT-302. Sozinibercept (OPT-302) is
- Study Identifies How Diabetes Slows Healing in the Eyehttps://modernod.com/news/study-identifies-how-diabetes-slows-healing-in-the-eye/2481742/Investigators from Cedars-Sinai have provided new understanding of how diabetes delays wound healing in the eye, identifying for the first time two related disease-associated changes to the cornea, according to a company news release.